Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BULLSEYE: Double Dose Beta-Lactams in Sepsis
NCT06766461Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in sepsis and septic shock (2 arms), sponsored by Erasmus MC. Primary endpoint: All-cause 28-day mortality. Started Jan 2025; status: recruiting.
02
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT06766461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766461.